Copyright: ©Author(s) 2026.
World J Gastroenterol. Dec 7, 2026; 32(45): 122564
Published online Dec 7, 2026. doi: 10.3748/wjg.122564
Published online Dec 7, 2026. doi: 10.3748/wjg.122564
Figure 1 Temporal relationship of tirzepatide use, symptom severity, and body mass index.
Symptom severity improved with tirzepatide initiation and re-initiation, worsened after dose reduction and discontinuation, and paralleled changes in drug exposure. Body mass index decreased during treatment and subsequently stabilized. BMI: Body mass index.
- Citation: Adeniran O, Almusabeh H, Adekolu A, Diab K, Hadam J, Bham NS, Sobani ZA. Tirzepatide for refractory post-fundoplication dumping syndrome: A case report. World J Gastroenterol 2026; 32(45): 122564
- URL: https://www.wjgnet.com/1007-9327/full/v32/i45/122564.htm
- DOI: https://dx.doi.org/10.3748/wjg.122564